Abigail S Friedman1. 1. Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA.
Abstract
BACKGROUND AND AIMS: Responses to the 2019 US outbreak of 'e-cigarette or vaping product use-associated lung injury' (EVALI) ranged from temporary restrictions on nicotine e-cigarette sales to critiques of state cannabis policies. However, if either mass-marketed nicotine e-cigarettes or cannabis use per se drove this outbreak, as opposed to an additive in regionally available black-market e-liquids, states' rates of vaping and/or cannabis use should predict their EVALI prevalence. This study tests that relationship. DESIGN: Observational study of EVALI data from US states' health departments SETTING: United States. PARTICIPANTS: All US states (n = 50). MEASUREMENTS: The outcome of interest was each state's total EVALI cases per 12-64-year-old resident-an age group covering most EVALI patients-as reported in the second week of January 2020. Predictors are 2017-18 rates of adult e-cigarette use and past-month cannabis use by state. FINDINGS: The average state EVALI prevalence was 1.4 cases per 100 000 12-64-year-olds. Maps suggest a high-prevalence cluster comprising seven contiguous states in the northern Midwest. EVALI cases per capita were negatively associated with rates of vaping and past-month cannabis use, with the preferred specification's coefficients at -0.239 [95% confidence interval (CI) = -0.441, -0.037; P = 0.02] and -0.086 (95% CI = -0.141, -0.031; P = 0.003), respectively. Robustness checks supported this finding. CONCLUSIONS: In the United States, states with higher rates of e-cigarette and cannabis use prior to the 2019 'e-cigarette or vaping product use-associated lung injury' (EVALI) outbreak had lower EVALI prevalence. These results suggest that EVALI cases did not arise from e-cigarette or cannabis use per se, but rather from locally distributed e-liquids or additives most prevalent in the affected areas.
BACKGROUND AND AIMS: Responses to the 2019 US outbreak of 'e-cigarette or vaping product use-associated lung injury' (EVALI) ranged from temporary restrictions on nicotine e-cigarette sales to critiques of state cannabis policies. However, if either mass-marketed nicotine e-cigarettes or cannabis use per se drove this outbreak, as opposed to an additive in regionally available black-market e-liquids, states' rates of vaping and/or cannabis use should predict their EVALI prevalence. This study tests that relationship. DESIGN: Observational study of EVALI data from US states' health departments SETTING: United States. PARTICIPANTS: All US states (n = 50). MEASUREMENTS: The outcome of interest was each state's total EVALI cases per 12-64-year-old resident-an age group covering most EVALI patients-as reported in the second week of January 2020. Predictors are 2017-18 rates of adult e-cigarette use and past-month cannabis use by state. FINDINGS: The average state EVALI prevalence was 1.4 cases per 100 000 12-64-year-olds. Maps suggest a high-prevalence cluster comprising seven contiguous states in the northern Midwest. EVALI cases per capita were negatively associated with rates of vaping and past-month cannabis use, with the preferred specification's coefficients at -0.239 [95% confidence interval (CI) = -0.441, -0.037; P = 0.02] and -0.086 (95% CI = -0.141, -0.031; P = 0.003), respectively. Robustness checks supported this finding. CONCLUSIONS: In the United States, states with higher rates of e-cigarette and cannabis use prior to the 2019 'e-cigarette or vaping product use-associated lung injury' (EVALI) outbreak had lower EVALI prevalence. These results suggest that EVALI cases did not arise from e-cigarette or cannabis use per se, but rather from locally distributed e-liquids or additives most prevalent in the affected areas.
Authors: Allison M Glasser; Lauren Collins; Jennifer L Pearson; Haneen Abudayyeh; Raymond S Niaura; David B Abrams; Andrea C Villanti Journal: Am J Prev Med Date: 2016-11-30 Impact factor: 5.043
Authors: Benjamin C Blount; Mateusz P Karwowski; Peter G Shields; Maria Morel-Espinosa; Liza Valentin-Blasini; Michael Gardner; Martha Braselton; Christina R Brosius; Kevin T Caron; David Chambers; Joseph Corstvet; Elizabeth Cowan; Víctor R De Jesús; Paul Espinosa; Carolina Fernandez; Cory Holder; Zsuzsanna Kuklenyik; Jennifer D Kusovschi; Cody Newman; Gregory B Reis; Jon Rees; Chris Reese; Lalith Silva; Tiffany Seyler; Min-Ae Song; Connie Sosnoff; Carleen R Spitzer; Denise Tevis; Lanqing Wang; Cliff Watson; Mark D Wewers; Baoyun Xia; Douglas T Heitkemper; Isaac Ghinai; Jennifer Layden; Peter Briss; Brian A King; Lisa J Delaney; Christopher M Jones; Grant T Baldwin; Anita Patel; Dana Meaney-Delman; Dale Rose; Vikram Krishnasamy; John R Barr; Jerry Thomas; James L Pirkle Journal: N Engl J Med Date: 2019-12-20 Impact factor: 91.245
Authors: Benjamin C Blount; Mateusz P Karwowski; Maria Morel-Espinosa; Jon Rees; Connie Sosnoff; Elizabeth Cowan; Michael Gardner; Lanqing Wang; Liza Valentin-Blasini; Lalith Silva; Víctor R De Jesús; Zsuzsanna Kuklenyik; Cliff Watson; Tiffany Seyler; Baoyun Xia; David Chambers; Peter Briss; Brian A King; Lisa Delaney; Christopher M Jones; Grant T Baldwin; John R Barr; Jerry Thomas; James L Pirkle Journal: MMWR Morb Mortal Wkly Rep Date: 2019-11-15 Impact factor: 17.586
Authors: Enrique Boloña; Miguel Felix; Emanuel Vanegas; Carlos Vera Paz; Ivan Cherrez-Ojeda Journal: Am J Respir Crit Care Med Date: 2020-03-15 Impact factor: 21.405
Authors: Maciej L Goniewicz; Danielle M Smith; Kathryn C Edwards; Benjamin C Blount; Kathleen L Caldwell; Jun Feng; Lanqing Wang; Carol Christensen; Bridget Ambrose; Nicolette Borek; Dana van Bemmel; Karen Konkel; Gladys Erives; Cassandra A Stanton; Elizabeth Lambert; Heather L Kimmel; Dorothy Hatsukami; Stephen S Hecht; Raymond S Niaura; Mark Travers; Charles Lawrence; Andrew J Hyland Journal: JAMA Netw Open Date: 2018-12-07
Authors: Katherine East; Jessica L Reid; Robin Burkhalter; Olivia A Wackowski; James F Thrasher; Harry Tattan-Birch; Christian Boudreau; Maansi Bansal-Travers; Alex C Liber; Ann McNeill; David Hammond Journal: Nicotine Tob Res Date: 2022-08-06 Impact factor: 5.825
Authors: Ellen Boakye; Omar El Shahawy; Olufunmilayo Obisesan; Omar Dzaye; Albert D Osei; John Erhabor; S M Iftekhar Uddin; Michael J Blaha Journal: PLoS One Date: 2022-10-17 Impact factor: 3.752
Authors: Kyle T Ganson; Jason M Lavender; Rachel F Rodgers; Mitchell Cunningham; Jason M Nagata Journal: Eat Weight Disord Date: 2021-06-28 Impact factor: 4.652